Phase 3 study for people with Chronic Kidney Disease

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting

Phase Phase 3

Sponsor AstraZeneca

Registry number NCT07753993

Started 21 August 2026 Today 16 October 2026 Estimated completion 4 October 2030

Where this trial is running

Trial sites and the status recorded for each
Site	City	State or country	Status at this site
Research Site	Castle Hill	NSW	Not yet recruiting
Research Site	Fitzroy	VIC	Not yet recruiting
Research Site	Gosford	NSW	Recruiting
Research Site	Melbourne	VIC	Not yet recruiting
Research Site	Perth	WA	Not yet recruiting
Research Site	Southport	QLD	Recruiting
Research Site	St Leonards	NSW	Not yet recruiting
Research Site	Wollongong	NSW	Not yet recruiting
Research Site	Woolloongabba	QLD	Not yet recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over

Sex Anyone, regardless of sex

Healthy volunteers Not accepted

Enrolment target 7000

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Adults with confirmed CKD; UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges.

* On stable, patient maximum tolerated, labeled daily dose of ACEI or ARB for ≥4 weeks at least 28 days before screening.

Exclusion Criteria:

* BMI \<23 kg/m² at screening

* History of type 1 diabetes mellitus

* HbA1c ≥10% (86 mmol/mol) at screening

* Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema.

* Have had more than one episode of severe hypoglycemia within 180 days prior to screening, or hypoglycemia unawareness

* Acute coronary syndrome, major cardiac procedure, stroke, or TIA within 3 months prior to screening

* Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying

* History of acute or chronic pancreatitis

* History/family history (first degree) of medullary thyroid cancer or MEN2

Dates on the record

Started 21 August 2026

Estimated completion 4 October 2030

Registry last updated 9 September 2026

Checked by Voxsanity 11 October 2026

Results, publications and the official record

No results are posted on the official record yet.
No publications are listed on the official record yet.
Official record and contacts on ClinicalTrials.gov – contact details for each site are kept there, and are not copied onto this page.

Sources and dates

ClinicalTrials.gov – the record this page reformats
ClinicalTrials.gov processing date: 9 September 2026.
This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.

Voxsanity

Clinical trials recruiting in Australia, from the public registries · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial, which may be relevant to my care:

Trial: NCT07753993

Sponsor: AstraZeneca

Phase: Phase 3

Status: Recruiting

Condition: Chronic Kidney Disease

More information: https://clinicaltrials.gov/study/NCT07753993

Eligibility criteria, as the registry published them

Reproduced exactly, unedited. Written for researchers rather than for patients.

Inclusion Criteria:

Adults with confirmed CKD; UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges.
On stable, patient maximum tolerated, labeled daily dose of ACEI or ARB for ≥4 weeks at least 28 days before screening.

Exclusion Criteria:

BMI <23 kg/m² at screening
History of type 1 diabetes mellitus
HbA1c ≥10% (86 mmol/mol) at screening
Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema.
Have had more than one episode of severe hypoglycemia within 180 days prior to screening, or hypoglycemia unawareness
Acute coronary syndrome, major cardiac procedure, stroke, or TIA within 3 months prior to screening
Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
History of acute or chronic pancreatitis
History/family history (first degree) of medullary thyroid cancer or MEN2

A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a registered health practitioner to access unapproved therapeutic goods for individual patients.

Not medical advice. Voxsanity reformats information published by public registries. It does not give medical advice and is not a substitute for talking to your doctor.